{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:26:03Z","timestamp":1764332763695,"version":"3.37.3"},"reference-count":34,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100001446","name":"Economic Development Board - Singapore","doi-asserted-by":"publisher","award":["ICES\/11-322A02"],"award-info":[{"award-number":["ICES\/11-322A02"]}],"id":[{"id":"10.13039\/501100001446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["ICES\/11-322A02"],"award-info":[{"award-number":["ICES\/11-322A02"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2019,10,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Sirolimus (SIR) is a macrocyclic lactone antibiotic and used therapeutically as\na potent immunosuppressant for prophylaxis of kidney transplant rejection. The development of an oral\ndosage form is challenging because of very poor aqueous solubility (2.6\u00b5g\/ml). The oral bioavailability\nof SIR is only 15-20 % and is affected by food and other drugs. The main reasons for low bioavailability\nare intestinal degradation by enzymes especially by cytochrome P4503A4, efflux by P-glycoprotein and\nhepatic first-pass metabolism.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The main objective was to prepare a mouth dissolving film dosage form of amorphous SIR to\nimprove dissolution.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> Crystalline SIR was transformed to its form amorphous by milling for 2 h at room temperature.\nThermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and powder x-ray diffraction\n(PXRD) were used for characterisation. The stability of amorphous SIR was studied at 4\u00b0C and\n40\u00b0C\/75% RH. Amorphous SIR was formulated as oral films by melt extrusion with polyvinylpyrrolidone-\nvinyl acetate (PVP-VA), Soluplus\u00ae and hydroxypropyl cellulose (HPC) as carriers. The films were\ncharacterized for drug content, physical state, dissolution profile and stability at 4\u00b0C and 40\u00b0C\/75% RH.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The PRXD and DSC confirmed the conversion of crystalline SIR to amorphous form by milling.\nThe solubility of amorphous SIR was several folds higher than its crystalline form, but amorphous\nSIR was highly unstable at all tested temperatures (4\u00b0 and 40\u00b0C). The extruded films exhibited higher\ndissolution and stability compared to milled SIR powder alone, but the process of extrusion had some\ndetrimental effect on the chemical stability of amorphous SIR.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> The film formulations showed a significant improvement in the storage stability of the\namorphous form of SIR and the solubility advantage of the amorphous form was evident in the dissolution\ntesting. The oral films can potentially improve the bioavailability of SIR by absorption through the\nbuccal mucosa.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201816666190416123939","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T08:05:37Z","timestamp":1555488337000},"page":"663-671","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preparation, Characterization and Prevention of Auto-oxidation of Amorphous Sirolimus by Encapsulation in Polymeric Films Using Hot Melt Extrusion"],"prefix":"10.2174","volume":"16","author":[{"given":"Parijat","family":"Kanaujia","sequence":"first","affiliation":[{"name":"Institute of Chemical and Engineering Sciences, 1, Pesek Road Jurong Island, Singapore-627833, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ponnammal","family":"Poovizhi","sequence":"additional","affiliation":[{"name":"Institute of Chemical and Engineering Sciences, 1, Pesek Road Jurong Island, Singapore-627833, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai Kiong","family":"Ng","sequence":"additional","affiliation":[{"name":"Institute of Chemical and Engineering Sciences, 1, Pesek Road Jurong Island, Singapore-627833, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reginald B. H.","family":"Tan","sequence":"additional","affiliation":[{"name":"Institute of Chemical and Engineering Sciences, 1, Pesek Road Jurong Island, Singapore-627833, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"Amidon G.L.","year":"1995","unstructured":"Amidon G.L.; Lennern\u00e4s H.; Shah V.P.; Crison J.R.; A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995,12(3),413-420","journal-title":"Pharm Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.powtec.2015.05.012","volume":"285","author":"Kanaujia P.","year":"2015","unstructured":"Kanaujia P.; Poovizhi P.; Ng W.K.; Tan R.B.H.; Amorphous formulations for dissolution and bioavailability enhancement of poorly soluble APIs. Powder Technol 2015,285,2-15","journal-title":"Powder Technol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0939-6411(02)00061-9","volume":"54","author":"Breitenbach J.","year":"2002","unstructured":"Breitenbach J.; Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm 2002,54(2),107-117","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0378-5173(00)00617-7","volume":"213","author":"Simamora P.","year":"2001","unstructured":"Simamora P.; Alvarez J.M.; Yalkowsky S.H.; Solubilization of rapamycin. Int J Pharm 2001,213(1-2),25-29","journal-title":"Int J Pharm"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","volume":"22","author":"Wu C.Y.","year":"2005","unstructured":"Wu C.Y.; Benet L.Z.; Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005,22(1),11-23","journal-title":"Pharm Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/nano.2007.2.1.25","volume":"2","author":"Shen L.J.","year":"2007","unstructured":"Shen L.J.; Wu F.L.; Nanomedicines in renal transplant rejection--focus on sirolimus. Int J Nanomed 2007,2(1),25-32","journal-title":"Int J Nanomed"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","volume":"31","author":"Sehgal S.N.","year":"1998","unstructured":"Sehgal S.N.; Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998,31(5),335-340","journal-title":"Clin Biochem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1124\/jpet.301.1.174","volume":"301","author":"Paine M.F.","year":"2002","unstructured":"Paine M.F.; Leung L.Y.; Lim H.K.; Liao K.; Oganesian A.; Zhang M.Y.; Thummel K.E.; Watkins P.B.; Identification of a novel route of extraction of sirolimus in human small intestine: Roles of metabolism and secretion. J Pharmacol Exp Ther 2002,301(1),174-186","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"B101","DOI":"10.1016\/S0149-2918(00)89027-X","author":"MacDonald A.","year":"2000","unstructured":"MacDonald A.; Scarola J.; Burke J.T.; Zimmerman J.J.; Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000(22 Suppl B,),B101-121","journal-title":"Clin Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"B93","DOI":"10.1016\/S0149-2918(00)89026-8","author":"Meier-Kriesche H.U.","year":"2000","unstructured":"Meier-Kriesche H.U.; Kaplan B.; Toxicity and efficacy of sirolimus:\nRelationship to whole-blood concentrations. Clin Ther 2000(22 Suppl B,),B93-100","journal-title":"Clin Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1021\/mp400362v","volume":"10","author":"Onyesom I.","year":"2013","unstructured":"Onyesom I.; Lamprou D.A.; Sygellou L.; Owusu-Ware S.K.; Antonijevic M.; Chowdhry B.Z.; Douroumis D.; Sirolimus encapsulated liposomes for cancer therapy: Physicochemical and mechanical characterization of sirolimus distribution within liposome bilayers. Mol Pharm 2013,10(11),4281-4293","journal-title":"Mol Pharm"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/21691401.2012.742100","volume":"41","author":"Kim M.S.","year":"2013","unstructured":"Kim M.S.; Kim J.S.; Cho W.K.; Hwang S.J.; Enhanced solubility and oral absorption of sirolimus using D-\u03b1-tocopheryl polyethylene glycol succinate micelles. Artif Cells Nanomed Biotechnol 2013,41(2),85-91","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10847-010-9885-2","volume":"70","author":"Abdur R.M.","year":"2011","unstructured":"Abdur R.M.; Imran V.; Erem B.; Dilek D.E.; Rapamycin cyclodextrin complexation: Improved solubility and dissolution rate. J Incl Phenom Macro 2011,70,167-175","journal-title":"J Incl Phenom Macro"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijpharm.2012.07.055","volume":"438","author":"Hu X.","year":"2012","unstructured":"Hu X.; Lin C.; Chen D.; Zhang J.; Liu Z.; Wu W.; Song H.; Sirolimus solid self-microemulsifying pellets: Formulation development, characterization and bioavailability evaluation. Int J Pharm 2012,438(1-2),123-133","journal-title":"Int J Pharm"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1167\/iovs.14-15997","volume":"56","author":"Nieto A.","year":"2015","unstructured":"Nieto A.; Hou H.; Moon S.W.; Sailor M.J.; Freeman W.R.; Cheng L.; Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin. Invest Ophthalmol Vis Sci 2015,56(2),1070-1080","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/pharmaceutics10030155","volume":"10","author":"Shen Y.","year":"2018","unstructured":"Shen Y.; Li X.; Le Y.; Amorphous nanoparticulate formulation of sirolimus and its tablets. Pharmaceutics 2018,10(3),155-167","journal-title":"Pharmaceutics"},{"key":"ref=17","first-page":"369","volume":"4","author":"Emami S.","year":"2014","unstructured":"Emami S.; Valizadeh H.; Islambulchilar Z.; Zakeri-Milani P.; Development and physicochemical characterization of sirolimus solid dispersions prepared by solvent evaporation method. Adv Pharm Bull 2014,4(4),369-374","journal-title":"Adv Pharm Bull"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"9496","DOI":"10.3390\/molecules20069496","volume":"20","author":"Cho Y.","year":"2015","unstructured":"Cho Y.; Ha E.S.; Baek I.H.; Kim M.S.; Cho C.W.; Hwang S.J.; Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit\u00ae e. Molecules 2015,20(6),9496-9509","journal-title":"Molecules"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijpharm.2013.01.067","volume":"445","author":"Kim M.S.","year":"2013","unstructured":"Kim M.S.; Kim J.S.; Cho W.; Cha K.H.; Park H.J.; Park J.; Hwang S.J.; Supersaturatable formulations for the enhanced oral absorption of sirolimus. Int J Pharm 2013,445(1-2),108-116","journal-title":"Int J Pharm"},{"key":"ref=20","first-page":"2997","volume":"6","author":"Kim M.S.","year":"2011","unstructured":"Kim M.S.; Kim J.S.; Park H.J.; Cho W.K.; Cha K.H.; Hwang S.J.; Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine 2011,6,2997-3009","journal-title":"Int J Nanomedicine"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.3892\/mmr.2017.6540","volume":"15","author":"Sun H.","year":"2017","unstructured":"Sun H.; Gu X.; Liu K.; Fang C.; Tang M.; Applicability of electrospun polypropylene carbonate polymers as a drug carrier for sirolimus. Mol Med Rep 2017,15(6),4253-4258","journal-title":"Mol Med Rep"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/odi.12229","volume":"20","author":"Nudelman Z.","year":"2014","unstructured":"Nudelman Z.; Friedman M.; Barasch D.; Nemirovski A.; Findler M.; Pikovsky A.; Gutkind J.; Czerninski R.; Levels of sirolimus in saliva and blood following mouthwash application. Oral Dis 2014,20(8),768-772","journal-title":"Oral Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00280-015-2721-z","volume":"75","author":"Nudelman Z.","year":"2015","unstructured":"Nudelman Z.; Findler M.; Barasch D.; Nemirovski A.; Pikovsky A.; Kirmayer D.; Basheer M.; Gutkind J.S.; Friedman M.; Czerninski R.; Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application. Cancer Chemother Pharmacol 2015,75(5),969-974","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0897190017705811","volume":"31","author":"Clark A.B.","year":"2018","unstructured":"Clark A.B.; Chandrasekar I.; Nickleson J.; Novel route of sirolimus administration in a neonate. J Pharm Pract 2018,31(2),167-168","journal-title":"J Pharm Pract"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejpb.2014.05.008","volume":"88","author":"Carvalho S.R.","year":"2014","unstructured":"Carvalho S.R.; Watts A.B.; Peters J.I.; Liu S.; Hengsawas S.; Escotet-Espinoza M.S.; Williams R.O.; Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats. Eur J Pharm Biopharm 2014,88(1),136-147","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jpba.2008.09.030","volume":"48","author":"Oyler A.R.","year":"2008","unstructured":"Oyler A.R.; Armstrong B.L.; Dunphy R.; Alquier L.; Maryanoff C.A.; Cohen J.H.; Merciadez M.; Khublall A.; Mehta R.; Patel A.; Il\u2019ichev Y.V.; Mass balance in rapamycin autoxidation. J Pharm Biomed Anal 2008,48(5),1368-1374","journal-title":"J Pharm Biomed Anal"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jpba.2011.10.017","volume":"59","author":"Oyler A.R.","year":"2012","unstructured":"Oyler A.R.; Segmuller B.E.; Sun Y.; Polshyna A.; Dunphy R.; Armstrong B.L.; Achord P.; Maryanoff C.A.; Alquier L.; Il\u2019ichev Y.V.; Forced degradation studies of rapamycin: Identification of autoxidation products. J Pharm Biomed Anal 2012,59,194-200","journal-title":"J Pharm Biomed Anal"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3998\/ark.5550190.0008.c09","volume":"2007","author":"Il\u2019ichev Y.V.","year":"2007","unstructured":"Il\u2019ichev Y.V.; Alquier L.; Maryanoff C.A.; Degradation of rapamycin and its ring-opened isomer: Role of base catalysis. ARKIVOC 2007,2007,110-131","journal-title":"ARKIVOC"},{"key":"ref=29","first-page":"1","volume":"Vol. 52","author":"Okamoto P.","year":"1999","unstructured":"Okamoto P.; Lam N.;  Physics of crystal-to-glass transformationsSolid State Physics; Ehrenreich, H 1999,Vol. 52,1-135","journal-title":"Physics of crystal-to-glass transformationsSolid State Physics; Ehrenreich, H"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/jps.20939","volume":"96","author":"Descamps M.","year":"2007","unstructured":"Descamps M.; Willart J.F.; Dudognon E.; Caron V.; Transformation of pharmaceutical compounds upon milling and comilling: the role of T(g). J Pharm Sci 2007,96(5),1398-1407","journal-title":"J Pharm Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1208\/s12249-012-9801-8","volume":"13","author":"Trasi N.S.","year":"2012","unstructured":"Trasi N.S.; Byrn S.R.; Mechanically induced amorphization of drugs: a study of the thermal behavior of cryomilled compounds. AAPS PharmSciTech 2012,13(3),772-784","journal-title":"AAPS PharmSciTech"},{"key":"ref=32","author":"Maryanoff C.A.","year":"2008","unstructured":"Maryanoff C.A.; Six K.; Vandecruys R.; Solvent free amorphous rapamycin. US 7,393,952 B2, 2008","journal-title":"US 7,393,952 B2,"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"9496","DOI":"10.3390\/molecules20069496","volume":"20","author":"Cho Y.","year":"2015","unstructured":"Cho Y.; Ha E.S.; Baek I.H.; Kim M.S.; Cho C.W.; Hwang S.J.; Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit e. Molecules 2015,20(6),9496-9509","journal-title":"Molecules"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0378-5173(01)00891-2","volume":"231","author":"Craig D.Q.M.","year":"2002","unstructured":"Craig D.Q.M.; The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 2002,231(2),131-144","journal-title":"Int J Pharm"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T12:10:45Z","timestamp":1572351045000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171657\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201816666190416123939","relation":{},"ISSN":["1567-2018"],"issn-type":[{"type":"print","value":"1567-2018"}],"subject":[],"published":{"date-parts":[[2019,10,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}